0       0

2016 - The Fetus and Newborn Conference


CCS11 - #11* Controversies in the Management of Patent Ductus Arteriosus (Rx = .25 hr.) ACPE #0263-000-16-660-L01-P (1.25 contact hrs.)


Sep 30, 2016 8:00am ‐ Sep 30, 2016 9:15am

Expiration Date: Oct 27, 2019


Credits: None available.

Standard: $21.00

Description

Learning Objectives:

  • Describe clinical and physiological variables affecting patency of the ductus arteriosus.
  • Discuss the rationale for the medical or surgical closure of a patent ductus arteriosus.
  • Describe the risks and benefits of indomethacin, ibuprofen and surgery for closure of a PDA.


Speaker(s):

Disclosures

  • Richard Polin, MD:

    Disclosure:

    Discovery Labs
    Fisher Paykel
    Premier Research

    Relationship:

    Consultnat
    Consultant
    Consultant

Credits

  • 0.25 - Pharmacology
  • 1.75 - Physician
  • 1.75 - RN / NP (All RNs/Nurses except CA RNs)
  • 1.75 - CA RN/CA BRN
  • 1.25 - Pharmacist

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-speaker-name image
token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content